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Abstract
Background 18F-FDG is a glucose analogue that is taken
up by a wide range of malignancies. 18F-FDG PET-CT is
now firmly established as an accurate method for the
staging and restaging of various cancers. However, 18F-
FDG also accumulates in normal tissue and other non-
malignant conditions, and some malignancies do not take
up F18-FDG or have a low affinity for the tracer, leading to
false-positive and false-negative interpretations.
Methods PET-CT allows for the correlation of two separate
imaging modalities, combining both morphological and
metabolic information. We should use the CT to help
interpret the PET findings. In this article we will highlight
specific false-negative and false-positive findings that one
should be aware of when interpreting oncology scans.
Results We aim to highlight post-treatment conditions that
are encountered routinely on restaging scans that can lead
to false-positive interpretations. We will emphasise the
importance of using the CT component to help recognise
these entities to allow improved diagnostic accuracy.
Conclusion In light of the increased use of PET-CT, it is
important that nuclear medicine physicians and radiologists
be aware of these conditions and correlate the PET and CT
components to avoid misdiagnosis, over staging of disease
and unnecessary biopsies.
Keywords Oncologic imaging.PET/CT artifacts.
Treatment effects.False positives.False negatives
Introduction
[
18F] 2-fluoro-2deoxy-D-glucose (
18F-FDG) PET-CT imaging
has become firmly established as an excellent clinical tool in
the diagnosis, staging and restaging of cancer.
18F-FDG (a
glucose analog) is taken up by cells via glucose transporter
proteins. The glucose analog then undergoes phosphorylation
by hexokinase to FDG-6 phosphate. Unlike glucose, FDG-
phosphate does not undergo further metabolism and so
becomes trapped in the cell as the cell membrane is
impermeable to FDG-6 phosphate following phosphorylation
[1].
Malignant tumors have a higher metabolic rate and
generally express higher numbers of specific membrane
transporter proteins than normal cells. This results in
increased uptake of
18F-FDG by tumor cells and forms
the basis of FDG-PET imaging [2]. Glucose however acts
as a basic energy substrate for many tissues, and so
18F-
FDG activity can be seen both physiologically and in
benign conditions. In addition, not all tumors take up FDG
[3–5]. The challenge for the interpreting physician is to
recognize these entities and avoid the many pitfalls
associated with
18F-FDG PET-CT imaging.
In this article we discuss false-positive and false-
negative
18F-FDG PET-CT findings, common and atypical
physiological sites of FDG uptake, and benign pathological
causes of FDG uptake. We will focus on post-treatment
conditions that can result in false-positive findings. We will
highlight the importance of utilizing the CTcomponent of the
study, not only for attenuation correction but also in the
interpretation of the study. The CT component of
18F-FDG
PET-CT imaging can provide high-resolution anatomical
information, which enables more accurate staging and
assessment. For the purposes of this article, we refer to the
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DOI 10.1007/s13244-010-0062-3descriptive terms “false-positive” and “false-negative” find-
ings in the context of oncology imaging.
The authors acknowledge that there are recognized
causes of FDG uptake that are not related to malignancy;
however in this paper we refer to false-positive findings as
FDG uptake that is not tumor related.
Patient preparation
Tumor uptake of FDG is reduced in the presence of raised
serum glucose as glucose competes with FDG for uptake by
the membrane transporter proteins. In order to prevent
false-negative results, it is necessary for the patient to fast
for at least 4–6 h prior to the procedure [6]. Induction of a
euglycamic hypoinsulinaemic state also serves to reduce the
uptake of glucose by the myocardium and skeletal muscle.
In the fasting state, the decreased availability of glucose
results in predominant metabolism of fatty acids by the
myocardium. This reduces the intensity of myocardial
uptake and prevents masking of metastatic disease
within the mediastinum [6].
The radiotracer is administered intravenously (dose
dependent on both the count rate capability of the system
used and the patient’s weight), and the patient is left resting
in a comfortable position during the uptake phase (60–
90 min). Patient discomfort and anxiety can result in
increased uptake in skeletal muscles of the neck and
paravertebral regions. Muscular contraction immediately
prior to or following injection can result in increased FDG
activity in major muscle groups [6].
Patients are placed in a warm, quiet room with little
stimulation, as speech during the uptake phase is associated
with increased FDG uptake in the laryngeal muscles [7].
At our institution we perform the CT component with
arms up except for head and neck studies where the arms
are placed down by the side. This minimizes artifacts on
CT. Depending on the type of cancer, oral contrast to
label the bowel and intravenous contrast may also be
given. The CT is performed with a full dose similar to a
diagnostic CT, and lungs are analyzed following recon-
struction with a lung algorithm. The PET scan is
performed with 3–4 min per bed position; however the
Fig. 1
18F-FDG PET-CT per-
formed in a 65-year-old male
with colorectal cancer. On the
coronal PET images, a focus of
increased FDG uptake is seen at
the right lung base (black
arrow). Contrast CT does not
show any pulmonary nodules
but does demonstrate a liver
metastasis in the superior aspect
of the right lobe of the liver
(yellow arrow)
680 Insights Imaging (2011) 2:679–698time per bed position will vary in different centers
depending on both the dose of FDG administered and the
specifications of the camera used for image acquisition.
It is beyond the scope of this article to provide detailed
procedure guidelines for
18F-FDG PET-CT imaging, and
for this purpose we refer the reader to a comprehensive
paper by Boellaard et al. [8].
Technical causes of false positives
Misregistration artifact
The evaluation of pulmonary nodules provides a unique
challenge for combined PET-CT scanning due to differences
in breathing patterns between CT and PET acquisition
Fig. 2
18F-FDG PET-CT
performed in a 28-year-old male
with an osteosarcoma of the
femur. A focus of increased
FDG uptake (yellow arrow) is
identified in the left lower lobe
with no CT correlate (a). A 3-
month follow-up CT thorax
again does not demonstrate any
pulmonary nodules confirming
that the uptake seen originally
on the PET-CT was due to
injected clot (b)
Insights Imaging (2011) 2:679–698 681periods. CT imaging of the thorax is classically performed
during a breath-hold; however PET images are acquired
during tidal breathing, and this can contribute signifi-
cantly to misregistration of pulmonary nodules on fused
PET-CT images. Misregistration is particularly evident
at the lung bases, which can lead to difficulty differ-
entiating pulmonary nodules from focal liver lesions
(Fig. 1)[ 9].
Acquiring CT imaging of the thorax during quiet
respiration can help to minimize misregistration artifacts.
It is also important to correlate your PET and CT
findings by scrolling up and down to make sure that
lesions match.
Injected clot A further diagnostic pitfall in staging of
intrathoracic disease can be caused by injected clot.
Injection of radioactive clot following blood withdrawal
into the syringe at the time of radiotracer administration can
result in pulmonary hotspots [10]. The absence of a CT
correlate for a pulmonary hotspot should raise the possibility
of injected clot; however this is a diagnosis of exclusion,
and it is important to carefully evaluate the adjacent slices
to ensure the increased radiotracer activity does not relate to
misregistration of a pulmonary nodule or hilar lymph node.
The area of abnormal radiotracer uptake should also be
closely evaluated on subsequent restaging CT to ensure there
has been no interval development of an anatomical abnor-
mality in the region of previously diagnosed injected clot
(Fig. 2)[ 11].
Injection artifact
Leakage of radiotracer into the subcutaneous tissues at the
injection site or tissued injection can result in subcutaneous
tracking of FDG along lymphatic channels in the arm. This
can result in spurious uptake in axillary nodes distal to the
injection site [12]. Careful attention must be paid to the
technical aspects of the study to ensure accurate staging.
Injection at the side contralateral to the site of disease is
advised where feasible to allow differentiation between
artifactual and metastatic uptake, particularly in breast
cancer patients. The side of injection should also be clearly
documented during administration of radiotracer, and this
Fig. 3
18F-FDG PET-CT
performed in a 56-year-old
woman with colorectal cancer.
Some low grade FDG uptake
is identified in non-enlarged
right axillary nodes
(yellow arrow) consistent
with injection artifact
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18F-FDG PET-CT
surveillance scan performed
in a 36-year-old male with a
history of seminoma. Symmet-
rical uptake is noted in the neck,
supraclavicular fossa and para-
vertebral regions consistent
with typical appearance of
brown fat activity (black arrow).
Brown fat uptake is also seen
in the left supradiaphragmatic
region and left paraoesophageal
region (yellow arrow)
(a).
18F-FDG PET-CT per-
formed in a 48-year-old male
with a history of colorectal
cancer. Increased FDG uptake
is noted within brown fat
associated with lipomatous
hypertrophy of the intra-atrial
septum (b)
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18F-FDG PET-CT
performed in a 42-year-old pre-
menopausal female with breast
cancer. She was scanned during
menstruation. FDG uptake is
noted within metastatic right
axillary nodes (black arrow).
Increased FDG uptake is
also noted within the endome-
trial canal of the uterus
(yellow arrow), which is
thickened on CT, consistent
with active menstruation
(a).
18F-FDG PET-CT per-
formed in the same 42-year-old
woman at a different stage in her
menstrual cycle showing reso-
lution of the previously identi-
fied uterine uptake (yellow
arrow) (b)
684 Insights Imaging (2011) 2:679–698information should be available to the reader in order to
ensure pathological FDG uptake is not spuriously attributed
to injection artifact (Fig. 3).
Imaging of metallic implants The use of CT for attenuation
correction negates the need for traditional transmission
attenuation correction, reducing scanning time. There are
however technical factors relating to the use of CT imaging
for attenuation correction, which lead to artefacts when
imaging metal [9]. The presence of metal implants in the
body produces streak artifact on CT imaging and degrades
image quality. When CT images are used for attenuation
correction, the presence of metal results in over attenuation
of PET activity in this region and can result in artifactual
‘hot spots.’ Metal prostheses, dental fillings, indwelling
ports and breast expanders and sometimes contrast media
are common causes of streak artifact secondary to high
photon absorption and can cause attenuation correction
artifacts [9]. In order to avoid false positives, particularly
when imaging metallic implants careful attenuation should
be paid to the nonattenuation corrected images, which do
not produce this artifact.
Sites of physiological FDG uptake
Physiological uptake in a number of organs is readily
recognized and rarely confused with malignancy. These
include cerebral tissue, the urinary system, liver and spleen.
Approximately 20% of administered activity is renally
excreted in the 2 h post-injection resulting in intense
radiotracer activity in the renal collecting systems, ureters
and bladder [13]. In order to minimize the intensity of renal
activity, patients are advised to void prior to imaging.
Moderate physiological FDG uptake is noted in the liver,
spleen, GI tract and salivary glands. Uptake in the cecum
and right colon tends to be higher than in the remainder of
the colon due to the presence of glucose-avid lymphocytes
[14].
Other sites of physiological FDG activity can be
confused with malignancy. Examples include activity
within brown fat, adrenal activity, uterus and ovaries.
Brown fat FDG uptake in hyper-metabolic brown adipose
tissue is well recognized as a potential source of false
positive in
18F-FDG PET-CT imaging. The incidence of
Fig. 6
18F-FDG PET-CT
performed in a 50-year-old
woman with inflammatory
breast cancer. Diffuse increased
FDG uptake is noted within the
right breast (yellow arrow)
and in a right axillary node
(black arrow), consistent with
malignancy (a). Increased
symmetrical uptake is also
noted within both adrenal
glands with no abnormal corre-
late on CT (yellow arrow) (b).
Post-chemotherapy PET-CT
performed 5 months later
demonstrates resolution of the
activity within the breast,
increased uptake in the bone
marrow consistent with post
treatment effect (black arrow)
and persistent increased uptake
in the adrenal glands (yellow
arrow), confirming benign
physiological activity (c)
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686 Insights Imaging (2011) 2:679–698FDG uptake in brown fat has been reported as between
2.5–4% [15, 16].
Hypermetabolic brown fat is more commonly identified
in children than in adults and is more prevalent in females
than in males. It occurs more frequently in patients with
low body mass index and in cold weather [15].
Glucose accumulation within brown fat is increased by
sympathetic stimulation as brown fat is innervated by the
sympathetic nervous system. In view of this, administration
of oral propranolol is advised by some authors as it has
been shown to reduce the uptake of FDG by brown fat [17].
This is not performed at our institution; however, attempts
are made to reduce FDG uptake in brown fat by maintaining a
warm ambient temperature and providing patients with
blankets during the uptake phase.
The typical distribution of brown fat in a bilateral
symmetric pattern in the supraclavicular and neck regions
is rarely confused with malignancy. In cases where hyper-
metabolic brown fat is seen to surround lymph nodes, the
CT images should be separately evaluated to allow
morphological assessment of the lymph nodes. The
classical CT features of pathological replacement of lymph
nodes should be sought, namely increased short axis
diameter, loss of the fatty hilum and loss of the normal
concavity of the lymph node. If the morphology of the
lymph node is entirely normal, malignancy can be
confidently excluded and the increased uptake attributed
to brown fat [18].
Atypical brown fat in the mediastinum can be misinter-
preted as nodal metastases and has been identified in the
paratracheal, paraoesophageal, prevascular regions, along
the pericardium and in the interatrial septum. Extramedias-
tinal sites of brown fat uptake include the paravertebral
regions, perinephric, perihepatic and subdiaphragmatic
regions and in the intraatrial septum [16].
The absence of an anatomical lesion on CT imaging in
areas of FDG uptake should raise the possibility of brown
fat to the reader. Careful evaluation of the CT images must
be performed to confirm the presence of adipose tissue in
the anatomical region correlating to the increased FDG
activity on
18F-FDG PET before this activity be attributed
to brown fat.
An awareness of the possibility of brown fat in atypical
locations is vital to avoid overstaging, and correlation with
CT imaging increases reader confidence in differentiating
brown fat from malignancy (Fig. 4).
Uterine and ovarian uptake In premenopausal women
endometrial uptake of FDG varies cyclically and is
increased both at ovulation and during the menstrual phase
of the cycle with mean SUV values of 3.5–5[ 19].
Endometrial uptake in postmenopausal women is abnormal
and warrants further investigation; however benign explan-
ations for increased FDG uptake include recent curettage,
uterine fibroids and endometrial polyps [19].
Benign ovarian uptake of FDG in premenopausal
women can be associated with ovulation. In postmeno-
pausal women, ovarian uptake of FDG should be further
investigated (Fig. 5).
Adrenal uptake
18F-FDG PET imaging is commonly used
for evaluation of adrenal masses in patients with diagnosed
malignancies. Similarly incidental adrenal lesions are
commonly identified on staging
18F-FDG PET-CT imaging.
The positive predictive value of
18F-FDG PET-CT evalua-
tion of adrenal lesions has been reported as high as 95%
with a similarly high negative predictive value of 94% [20].
Causes of false-positive adrenal lesions include angio-
myolipoma, adrenal hyperplasia and adrenal adenomas (up
to 5%) [21, 24]. FDG activity greater than that of the liver
is generally associated with malignancy; however benign
lesions have been reported with greater activity than liver
[21].
Evaluation of the CT component can provide additional
diagnostic information with identification of HU attenu-
ation values of <10 on noncontrast CT for adrenal
adenomas or fat-containing myelolipomata [21].
Symmetrical intense FDG activity with no identifiable
abnormality on CT is associated with benign physiological
FDG uptake (Fig. 6).
Thyroid uptake
Thyroid uptake is incidentally identified on
18F-FDG PET
imaging with a frequency of almost 4%, with a diffuse
uptake pattern in roughly half of cases and a focal pattern in
the remainder [22]. The majority of diffuse uptake
represents chronic thyroiditis, multinodular goiter or
Graves' disease, whereas focal uptake is associated with a
risk of malignancy that ranges from 30.9–63.6% in
published studies [22, 23]. Focal thyroid uptake requires
further investigation with ultrasound and tissue biopsy.
Uptake in the gastrointestinal tract
The pattern of physiological uptake within the GI tract is
highly variable. Low-grade linear uptake is likely related to
smooth muscle activity and swallowed secretions. More
focal increased uptake in the distal esophagus is sometimes
seen with Barrett's esophagus. In view of this, referral for
OGD may be reasonable in cases of increased uptake in the
distal esophagus [14, 24].
The typical pattern of FDG uptake in the stomach is of
low-grade activity in a J-shaped configuration. Small bowel
typically demonstrates mild heterogeneous uptake through-
out. Common pitfalls of small bowel evaluation relate to
Insights Imaging (2011) 2:679–698 687spuriously high uptake in underdistened or overlapping
loops of bowel [14, 25].
Within the colon, FDG uptake is highly variable,
however can be quite avid particularly in the cecum, right
colon and rectosigmoid regions. Focal areas of FDG
activity within the colon that are of greater intensity than
background liver uptake should raise the suspicion of a
colonic neoplasm (Fig. 7)[ 25, 26].
In a review of over 3,000 patients' focal areas of
abnormal FDG uptake within the gastrointestinal tract
(GIT) were identified in 3% of cases of staging
18F-FDG
PET-CT studies.
Incidental malignant lesions were identified in 19% of
these patients with pre-malignant lesions including adenomas
in42%ofthepatients[27]. In view of this endoscopy referral
is recommended in the absence of a clear benign correlate
for focal areas of avid uptake on CT imaging.
Treatment-related causes of false-positive uptake
There are a number of conditions that can occur in patients
undergoing treatment for cancer. When imaging these
patients to assess for response, we often see these
treatment-related conditions. It is important to recognize
the imaging features to avoid misdiagnosis.
Thymus/thymic hyperplasia
Thymic hyperplasia post-chemotherapy is a well-described
phenomenon. It is generally seen in children and young
adults at a median of 12 months post chemotherapy [28].
The presence of increased FDG uptake in the anterior
mediastinum can be attributed to thymic hyperplasia by
identification of a triangular soft tissue density seen
retrosternally on CT with a characteristic bilobed anatom-
ical appearance [29]. In the presence of thymic hyperplasia,
there is generally preservation of the normal shape of the
gland despite an increase in size [30].
Superior mediastinal extension of thymic tissue is an
anatomical variant that has been described in children and
young adults (Fig. 8).
It presents as a soft tissue nodule anteromedial to the left
brachiocephalic vein and represents a remnant of thymic
tissue along the path of migration in fetal life. In patients
with thymic hyperplasia, a superior mediastinal nodule in
this location may represent accessory thymic tissue. An
Fig. 7
18F-FDG PET-CT
restaging scan performed in a
65-year-old female with a his-
tory of breast cancer. Incidental
focal uptake is identified in the
ascending colon where some
abnormal thickening is
seen on the CT component
(yellow arrow). Colonoscopy
confirmed the presence of
a T3 adenocarcinoma
688 Insights Imaging (2011) 2:679–698Fig. 8 A 3.5-year-old boy with
abdominal Burkitt's lymphoma.
Coronal
18F-FDG PET scan
obtained 5 months after comple-
tion of treatment shows increased
activity in the thymus in an
inverted V configuration and in
superior thymic extension (white
arrow). Note physiologic activity
within the right neck in the
sternocleidomastoid muscle (a).
Axial CT image from the same
18F-FDG PET-CT study
performed 5 months after treat-
ment shows a nodule (white
arrow) anteromedial to the left
brachiocephalic vein (b). Axial
fusion image shows that the FDG
activity in the superior mediasti-
num corresponds to this enlarged
nodule anteromedial to left
brachiocephalic vein (white
arrow) (c). Axial fusion image
shows increased activity in an
enlarged thymus consistent with
thymic hyperplasia (white arrow;
standardized uptake value 3.0) of
similar intensity to activity in
superior mediastinum (d)
Fig. 9
18F-FDG PET-CT
performed in a 46-year-old male
post four cycles of chemother-
apy for lymphoma and 2 weeks
post administration of G-CSF.
Note the diffuse homogeneous
increased uptake throughout
the bone marrow and the
increased uptake in the spleen
(yellow arrow)
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18F18-FDG PET-CT
performed in a 52-year-old
male with newly diagnosed
esophageal carcinoma. Increased
FDG uptake is identified within
the esophagus (black arrow) and
an upper abdominal lymph node
(yellow arrow), consistent with
malignancy (a).
18F18-FDG
PET-CT performed 6 weeks
post-completion of radiotherapy
for esophageal carcinoma. Linear
increased uptake is identified
along the mediastinum in the
radiation port (black arrow). This
corresponds to areas of ground-
glass change on CT (yellow
arrow) consistent with acute
radiation change (b)
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18F-FDG PET-CT
performedina57-year-oldmale2
weeks following chemotherapy
for lung cancer. Increased FDG
uptake is noted within
the cecum (black arrow). On
CT there is some thickening of
thececal wallandstrandingofthe
pericecal fat (yellow arrow)
consistent with typhilits
Fig. 12
18F-FDG PET-CT
performed in a 69-year-old
male with a history of
non-Hodgkin's lymphoma. The
patient had a previous talc
pleurodesis for a persistent left
pleural effusion. Increased FDG
activity is identified within the
left pleura (black arrow). CT
demonstrates a pleural effusion
with high density material along
the left pleural surface consistent
with talc (yellow arrow)
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prevent misdiagnosis [28].
G-CSF changes
Granulocyte colony-stimulating factor is a glycoprotein
hormone that regulates proliferation and differentiation of
granulocyte precursors. It is used to accelerate recovery
from chemotherapy-related neutropaenia in cancer patients.
Intense increased FDG uptake is commonly observed in the
bone marrow and spleen following GCSF therapy; however
the bone marrow response to GCSF can be differentiated
from pathological infiltration by its intense homogeneous
nature without focally increased areas of FDG uptake.
Increased FDG uptake attributable to GCSF uptake rapidly
decreases following completion of therapy and generally
resolves within a month (Fig. 9).
Marked uptake in the bone marrow can also be seen
following chemotherapy, reflecting marrow activation [31, 32].
Radiation pneumonitis Inflammatory morphological
changes in the radiation field post-irradiation of primary
or metastatic lung tumor can result in false-positive
diagnosis. Radiation pneumonitis typically occurs fol-
lowing high doses of external beam radiotherapy (>40
Gy). In the acute phase (1–8 weeks) radiation pneumo-
nitis is characterized by ground-glass opacities and
patchy consolidation. This can commonly lead to a
misdiagnosis of infection. Chronic CT appearances of
fibrosis and traction bronchiectasis in the radiation field
allow correct interpretation of increased FDG uptake as
radiation pneumonitis as opposed to disease recurrence
[33, 34]. Other organs are also sensitive to radiation, and
persistent uptake due to inflammatory change can persist
for up to 1 year. It is important to elicit a history of
radiation from the patient and to correlate the increased
uptake with the CT findings to avoid missing a disease
recurrence (Fig. 10).
Infection
Bone marrow suppression places chemotherapy patients at
increased risk of infection.
Fig. 13
18F-FDG PET-CT
performed in a 46-year-old
gentleman with a history of
non-Hodgkin's lymphoma.
Increased FDG uptake is identi-
fied in the right proximal
humerus (black arrow). CT of
the area demonstrates a corre-
sponding vague area of sclerosis
(yellow arrow). Biopsy of the
area yielded osteonecrosis with
no evidence of metastatic
disease
692 Insights Imaging (2011) 2:679–698Inflammatory cells such as neutrophils and activated
macrophages at the site of infection or inflammation
actively accumulate FDG [35].
In the post-therapy setting it has been reported that up to
40% of FDG uptake occurs in non-tumor tissue [12].
Infection is one of the most common causes of false-
positive
18F-FDG PET-CT findings post-chemotherapy.
Chemotherapy patients are susceptible to a wide variety of
infections, including upper respiratory chest infections,
pneumonia, colitis and cholecystitis. Reactivation of tuber-
culous infection can occur in immunocompromised patients
post,chemotherapy, and correlation with CT imaging can
prevent misdiagnosis in suspected cases.
Atypical infections such as cryptococcosis and pneumo-
cystis can also present as false-positives on FDG imaging
(Fig. 11)[ 36].
Surgery and radiotherapy
There are inherent challenges in the interpretation of
18F-
FDG PET-CT imaging in the postoperative patient. Non-
tumor-related uptake of FDG is frequently identified in
post-operative wound sites, at colostomy sites or at the site
of post-radiation inflammatory change.
18F-FDG PET-CT
imaging during the early postoperative/post-radiotherapy
period may result in overstaging of patients because of
non-neoplastic uptake of FDG [12]. Careful evaluation of
the CT component in this setting is vital as CT imaging
can provide valuable additional information regarding
benign inflammatory conditions commonly encountered
in the postoperative setting such as abscesses or wound
infection. These conditions are often readily apparent on
CT, particularly when oral and/or IV contrast CT is
administered.
T h er e a d e rs h o u l da l s ob e a ri nm i n dt h a ta v i du p t a k eo f
FDG at postoperative/post radiotherapy sites may mask
malignant FDG uptake in neighboring structures. In order to
minimize non-tumoral uptake of FDG, it is advisable to allow
at least 6 weeks post-surgery or completion of radiotherapy
prior to performing staging
18F-FDG PET-CT [24].
Talc pleurodesis Talc pleurodesis is a commonly performed
procedure for the treatment of persistent pneumothorax or
pleural effusion. The fibrotic/inflammatory reaction results
in increased FDG uptake on
18F-FDG PET imaging with
corresponding high-density areas of pleural thickening on
Fig. 14
18F-FDG PET-CT per-
formed in a 46-year-old female,
3 years post-chemo-radiation for
cervical carcinoma. Low grade
FDG uptake is identified in the
left acetabulum and right pubic
bone (black arrow). CT demon-
strates pathological fractures in
these areas consistent with
insufficiency fractures (yellow
arrow)
Insights Imaging (2011) 2:679–698 693CT. SUV values of between 2–16.3 have been seen years
after the procedure [37].
When increased FDG uptake is indentified in the pleural
space in a patient with a known history of pleurodesis,
correlation with CT is recommended to detect pleural
thickening of increased attenuation that suggests talc rather
than tumor.
It is extremely important that a comprehensive history
with relevant surgical interventions is available to the
reader in order to ensure accurate diagnosis and staging
(Fig. 12).
Flare phenomenon Bone healing is mediated by osteo-
blasts, and an early increase in osteoblast activity on
successful treatment of metastatic disease has been
described [38]. “Bone flare” refers to a disproportionate
increase in bone lesion activity on isotope bone scan
despite evidence of a therapeutic response to treatment
in other lesions and has been well described in breast,
prostate and lung tumors. ‘Flare phenomenon’ has also
been described on
18F-FDG PET-CT in patients with
lung and breast cancer who are receiving chemotherapy
[39].
Differentiating between increased FDG uptake due to
flare response and true disease progression may not be
possible in the early post-treatment studies. While it is
recognized that bone flare is a rare phenomenon, an
increase in baseline skeletal activity and appearance of
new bone lesions despite apparent response or stable
disease elsewhere should be interpreted with caution to
avoid erroneously suggesting progressive disease.
Osteonecrosis Osteonecrosis or avascular necrosis has been
well described as a complication of combination chemo-
therapy treatment, especially where it includes intermittent
high-dose corticosteroids (e.g., lymphoma patients) [40].
Commonly encountered sites include the hip and less
frequently the proximal humerus. Occasionally we can see
a discrete entity known as jaw osteonecrosis. Patients
receiving IV bisphosphonates for the management of bone
Fig. 15
18F-FDG PET-CT per-
formed in a 67-year-old male for
restaging of laryngeal carci-
noma. Increased FDG uptake is
noted in the left lower
neck and left mediastinum
(black arrow). CT demonstrates
lymphadenopathy in these
areas (yellow arrow), some
of which are calcified. Biopsy
of the left lower neck node
confirmed sarcoidosis
694 Insights Imaging (2011) 2:679–698metastases are at an increased risk of developing this [41].
The development of osteonecrosis in the mandible is
frequently preceded by tooth extraction. Radiographic
findings that may be visualized on CT include osteoscle-
rosis, dense woven bone, thickened lamina dura and
sub-periosteal bone deposition [42]. FDG uptake can be
seen in areas of osteonecrosis (Fig. 13).
Insufficiency fractures Pelvic insufficiency fractures have
been described following irradiation for gynecological,
colorectal, anal and prostate cancer. They commonly occur
within 3–12 months post-radiation treatment, and osteopo-
rosis is often a precipitating factor. FDG uptake in
insufficiency fractures ranges from mild and diffuse to
intense and heterogeneous. The maximum SUV values are
variable with reported values of between 2.4–7.2 [43].
Differentiating insufficiency fractures from bone metastases
can prove challenging; however they are often bilateral and
occur in characteristic locations within the radiation field—
sacral ala, pubic rami and iliac bones. Biopsy of insuffi-
ciency fractures can lead to irreparable damage and so
careful correlation of
18F-FDG PET imaging with the CT
component along with radiation history is vital for correct
diagnosis. CT allows evaluation of the bone cortex and
adjacent soft tissues, which can confirm the diagnosis of a
pathological fracture or a metastatic deposit.
Follow-up of suspected insufficiency fractures demon-
strates a reduction in FDG uptake over time (Fig. 14)[ 43].
Sarcoidosis Sarcoidosis is a chronic multisystem disorder
characterized by non-caseating granulomas and derange-
ment of normal tissue architecture [36]. Sarcoidosis has
been reported in association with a variety of malignancies
either synchronously or post-chemotherapy. Aggregation of
inflammatory cells post-chemotherapy is associated with
accumulation of FDG, and the intensity of FDG uptake
may correlate with disease activity [36].
When suspected disease recurrence presents with signs
and symptoms compatible with sarcoidosis (i.e., mediastinal
and bihilar lymphadenopathy), this must be excluded by
clinical, radiological and pathological correlation to prevent
mistreatment (Fig. 15).
Fig. 16
18F-FDG PET-CT per-
formed in a 52-year-old female
with breast cancer and chronic
hepatitis. On the CT component
a hyper-enhancing mass is iden-
tified in segment 4 of the liver
(yellow arrow). No increased
FDG activity is identified in this
area on the PET component.
Biopsy of the mass confirmed
the diagnosis of a hepatocellular
carcinoma
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There are a number of malignancies that can be FDG-PET
negative. Examples include bronchoalveolar carcinoma and
carcinoid tumors in the lung, renal cell carcinomas and
hepatomas, mucinous tumors of the GITand colon, and low
grade lymphomas [3, 44–48]. Careful evaluation of the CT
component of the study however will prevent a misdiag-
nosis (Fig. 16).
Osteoblastic metastases
Bone metastases are diagnosed in up to 85% of patients
with advanced breast cancer, leading to significant morbidity
and mortality. Sclerotic bone metastases are commonly
associatedwithbreastcarcinoma[49].
18F-FDG PET imaging
is superior to nuclear bone scan in detection of osteolytic
breast metastases; however it commonly fails to diagnose
osteoblastic or sclerotic metastases [50]. Review of bony
windows on CT imaging allows identification of sclerotic
metastases and ensures accurate staging of metastatic bone
disease (Fig. 17).
Discussion/conclusion
18F-FDG PET imaging has dramatically changed cancer
staging, and findings of restaging studies commonly
effect changes in treatment protocols.
18F-FDG however
is not tumor specific. As interpreting physicians we need
to be aware of these false positives and false negatives.
In this review we have outlined atypical physiological
sites of FDG uptake along with common causes of FDG
uptake in benign pathological conditions, many of which
are treatment related. With
18F - F D GP E T - C Tw eh a v et h e
advantage of two imaging modalities. The PET compo-
nent gives us functional information and the CT,
anatomical data. We have discussed the importance of
dual-modality imaging and correlation with CT imaging
of the above conditions. Furthermore CT imaging
provides important diagnostic information in evaluation
of tumors that poorly concentrate FDG. In light of the
increased reliance of
18F-FDG PET-CT for cancer
staging, it is vital that radiologists and nuclear medicine
physicians be aware of pitfalls in
18F-FDG PET-CT
imaging and correlate PET and CT components to avoid
Fig. 17 Staging
18F-FDG PET-
CT performed in a 45-year-old
female with newly diagnosed
breast cancer. CT demonstrates
multiple small sclerotic foci in
the spine and pelvis (yellow
arrow), consistent with bony
metastases. These are FDG
negative on the PET component
of the study
696 Insights Imaging (2011) 2:679–698misdiagnosis, overstaging of disease and unnecessary
biopsies.
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